Literature DB >> 31241355

Relationship of Metacognition and Insight to Neural Synchronization and Cognitive Function in Early Phase Psychosis.

Bethany L Leonhardt1, Jenifer L Vohs1,2, Lisa A Bartolomeo2, Andrew Visco1, William P Hetrick2, Amanda R Bolbecker2, Alan Breier1, Paul H Lysaker1,3, Brian F O'Donnell2.   

Abstract

Metacognition is the process of thinking about one's own mental states. It involves a range of faculties that allow an individual to integrate information and form understanding of self and others, and use this understanding to respond to life challenges. Clinical insight is the awareness of one's mental illness, its consequences, and the need for treatment. Persons with psychotic disorders show impaired metacognition and insight, but the neurobiological bases for these impairments are not well characterized. We hypothesized that metacognition and insight may depend on capacity of neural circuits to synchronize at gamma frequencies, as well as the integrity of underlying cognitive processes. In order to test these hypotheses, 17 adults with early phase psychosis were evaluated. Metacognition was assessed with the Metacognition Assessment Scale-Abbreviated, and insight was assessed with the Scale of Unawareness of Illness-Abbreviated. The auditory steady state response (ASSR) to gamma range stimulation (40 Hz) was used as an index of neural synchronization. Cognitive function was assessed using the Brief Assessment of Cognition in Schizophrenia. Increases in ASSR power were associated with poorer metacognition and insight. Higher cognitive performance was associated with higher levels of metacognitive function and insight. These findings suggest that altered neural synchronization and constituent cognitive processes affect both metacognition and insight in early phase psychosis and may offer targets for both pharmacological and psychotherapeutic interventions.

Entities:  

Keywords:  auditory steady state potential; gamma frequency; metacognition; psychosis; schizophrenia

Mesh:

Year:  2019        PMID: 31241355     DOI: 10.1177/1550059419857971

Source DB:  PubMed          Journal:  Clin EEG Neurosci        ISSN: 1550-0594            Impact factor:   1.843


  6 in total

1.  Effects of Cognitive Remediation on Cognition, Metacognition, and Social Cognition in Patients With Schizophrenia.

Authors:  Cristiana Montemagni; Elisa Del Favero; Cecilia Riccardi; Laura Canta; Mario Toye; Enrico Zanalda; Paola Rocca
Journal:  Front Psychiatry       Date:  2021-07-09       Impact factor: 4.157

Review 2.  Gamma-Range Auditory Steady-State Responses and Cognitive Performance: A Systematic Review.

Authors:  Vykinta Parciauskaite; Jovana Bjekic; Inga Griskova-Bulanova
Journal:  Brain Sci       Date:  2021-02-10

Review 3.  Abnormal ERPs and Brain Dynamics Mediate Basic Self Disturbance in Schizophrenia: A Review of EEG and MEG Studies.

Authors:  Arthur Hamilton; Georg Northoff
Journal:  Front Psychiatry       Date:  2021-04-12       Impact factor: 4.157

4.  Evaluating the feasibility of a decision aid to promote shared decision making among young adults with first-episode psychosis: protocol for a pilot study.

Authors:  Yaara Zisman-Ilani; Irene Hurford; Andrea Bowen; Mark Salzer; Elizabeth C Thomas
Journal:  Pilot Feasibility Stud       Date:  2021-01-11

5.  Persons with first episode psychosis have distinct profiles of social cognition and metacognition.

Authors:  M Ferrer-Quintero; D Fernández; R López-Carrilero; I Birulés; A Barajas; E Lorente-Rovira; L Díaz-Cutraro; M Verdaguer; H García-Mieres; J Sevilla-Llewellyn-Jones; A Gutiérrez-Zotes; E Grasa; E Pousa; E Huerta-Ramos; T Pélaez; M L Barrigón; F González-Higueras; I Ruiz-Delgado; J Cid; S Moritz; S Ochoa
Journal:  NPJ Schizophr       Date:  2021-12-09

6.  40-Hz auditory steady-state responses and the complex information processing: An exploratory study in healthy young males.

Authors:  Vykinta Parciauskaite; Aleksandras Voicikas; Vytautas Jurkuvenas; Povilas Tarailis; Mindaugas Kraulaidis; Evaldas Pipinis; Inga Griskova-Bulanova
Journal:  PLoS One       Date:  2019-10-07       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.